Daniel Goncher
Medical · Johnstown, PANPI 1629074000
Payments from drug & device makers
Across 526 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$960
- AbbVie$950
- Novo Nordisk$730
- GSK$601
- Lilly USA, LLC$503
- Tactile Systems Technology Inc$475
- plus $4K from 37 others
What the payments were for
- Food & beverage$8,286100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flexitouch Plus$229
- Nimbl$229
How this compares
$8,306 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $159,413 |
| OzempicSemaglutide | 96 | $122,944 |
| JardianceEmpagliflozin | 106 | $98,484 |
| TradjentaLinagliptin | 60 | $55,659 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $43,592 |
| MounjaroTirzepatide | 26 | $38,501 |
| XareltoRivaroxaban | 17 | $23,682 |
| TrulicityDulaglutide | 15 | $20,148 |
| JanuviaSitagliptin Phosphate | 12 | $19,315 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,564 |
| LinzessLinaclotide | 19 | $13,825 |
| EntrestoSacubitril/Valsartan | 14 | $11,647 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 13 | $8,381 |
| Rosuvastatin Calcium | 377 | $8,281 |
| Fenofibrate | 12 | $7,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $275 | $162,524179 claims |
| PfizerEliquis | $960 | $159,413187 claims |
| Novo NordiskOzempic | $730 | $122,94496 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $601 | $59,15788 claims |
| Lilly USA, LLCMounjaro, Trulicity | $503 | $58,64941 claims |
| Johnson & JohnsonXarelto | $172 | $23,68217 claims |
| MerckJanuvia | $257 | $19,31512 claims |
| AbbVieLinzess, Synthroid | $950 | $17,48994 claims |
| NovartisEntresto | $29 | $11,64714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $25 | $5,99312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Johnstown
- Karah McClellandJohnstown$14K
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.